Drug intelligence / Profile preview

MAGE3-TBHSP70

Development stage
Preclinical
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Subcutaneous
01

Overview

MAGE3-TBHSP70 is a recombinant fusion protein vaccine candidate designed for cancer immunotherapy. It consists of a specific segment of the melanoma-associated antigen 3 (MAGE-3), typically amino acids 195-314, covalently linked to the C-terminus of Mycobacterium tuberculosis heat shock protein 70 (HSP70). In this construct, HSP70 serves as a potent molecular adjuvant and chaperone that enhances the recruitment, uptake, and processing of the MAGE-3 antigen by professional antigen-presenting cells. This linkage is essential for eliciting a robust, antigen-specific immune response, including the activation of cytotoxic T lymphocytes (CTLs) and the production of cytokines. Preclinical studies have demonstrated that MAGE3-TBHSP70 can induce significant tumor regression and prolong survival in animal models of MAGE-3-expressing malignancies, such as melanoma, hepatocellular carcinoma, and pulmonary carcinoma.

Other names
HSP70-MAGE-3HSP-70-MAGE-3HSP 70-MAGE-3MAGE3/TBHSP70rMAGE3-TBHSP70rMAGE-3-TBHSP70rMAGE 3-TBHSP70recombinant MAGE3-TBHSP70
02

Targets

HSP70 (Heat shock protein 70)MAGEA3 (Melanoma-associated antigen 3)

Beyond the preview

Go deeper on MAGE3-TBHSP70.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAGE3-TBHSP70.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call